Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell death
Background
Combining immunotherapy with endocrine therapy and/or chemotherapy promotes prognosis in patients with estrogen receptor-positive/HER2-negative (ER+HER2–) breast cancer; however, the unclear underlying mechanisms limit their widesprea…